What is Bristol-Myers Squibb Co.'s earnings per share (EPS)?

Bristol-Myers Squibb Co. (BMY) reported diluted earnings per share of $3.46 for fiscal year 2025. This represents a 178.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Bristol-Myers Squibb Co. (BMY) Financials

BMY

Trailing 12 months to June 30, 2026

Revenue $49.2B +3.1% YoY

Net Income $9.3B +83.8% YoY

EPS (Diluted) $4.54 +83.1% YoY

Free Cash Flow $11.4B -21.5% YoY

Market Cap $121.7B as of Oct 7, 2026

Price / Sales 2.5x on $49.2B revenue, trailing 12 months to June 30, 2026

Price / Earnings 13.1x on $9.3B net income, trailing 12 months to June 30, 2026

Price / Book 5.5x on $22.3B equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 7, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Jul 30, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Jul 30, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BMY SEC filings page.

Bristol-Myers Squibb Co. (BMY) reported $49.2B in revenue over the twelve months to Jun 30, 2026, up 3.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BMY FY2025 2026-10-03

Cash generation remained durable through a one-year accounting loss, while debt made the balance sheet more sensitive to earnings swings.

In FY2024, net income swung to a net loss of $8.9B even as operating cash flow reached $15.2B, indicating earnings were heavily affected by non-cash or unusual charges rather than an equivalent collapse in cash production. FY2025 returned to net income of $7.1B while free cash flow was $12.8B, showing the earnings shock reversed without restoring FY2024's higher cash conversion.

Gross margin reset from 78.0% in FY2022 to 71.1% in FY2025. Because revenue stayed near $48B, the deterioration reflects a less favorable cost or product mix rather than simple volume weakness.

Debt-to-equity reached 2.9x in FY2024 as equity fell to $16.3B. It eased to 2.3x in FY2025 but remained above FY2023's 1.2x, leaving less equity cushion relative to debt.

Financial Health Signals

Financial Health Score 33/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Bristol-Myers Squibb Co.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Not available for Bristol-Myers Squibb Co., and counted as zero in the overall score.

Growth

Bristol-Myers Squibb Co.'s revenue declined 0.2% year-over-year, from $48.3B to $48.2B. This contraction results in a growth score of 43/100.

Leverage

Bristol-Myers Squibb Co. has elevated debt relative to equity (D/E of 2.32), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 28/100, reflecting increased financial risk.

Liquidity

Bristol-Myers Squibb Co.'s current ratio of 1.26 indicates adequate short-term liquidity, earning a score of 31/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Bristol-Myers Squibb Co. converts 26.7% of revenue into free cash flow ($12.8B). This strong cash generation earns a score of 93/100.

Returns

Not available for Bristol-Myers Squibb Co., and counted as zero in the overall score.

Piotroski F-Score Strong

7/9

Bristol-Myers Squibb Co. passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

2.01x

For every $1 of reported earnings, Bristol-Myers Squibb Co. generates $2.01 in operating cash flow ($14.2B OCF vs $7.1B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$13.0B

YoY+5.7%

QoQ+12.9%

5Y CAGR+2.1%

10Y CAGR+10.3%

Bristol-Myers Squibb Co. generated $13.0B in revenue in Q2 2026. This represents an increase of 5.7% from the same quarter a year earlier. Against the prior quarter it is up 12.9%.

Net Income

$3.3B

YoY+153.2%

QoQ+23.9%

5Y CAGR+25.7%

10Y CAGR+11.0%

Bristol-Myers Squibb Co. reported $3.3B in net income in Q2 2026. This represents an increase of 153.2% from the same quarter a year earlier. Against the prior quarter it is up 23.9%.

EPS (Diluted)

$1.62

YoY+153.1%

QoQ+23.7%

5Y CAGR+28.1%

10Y CAGR+8.9%

Bristol-Myers Squibb Co. earned $1.62 per diluted share (EPS) in Q2 2026. This represents an increase of 153.1% from the same quarter a year earlier. Against the prior quarter it is up 23.7%.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

$3.1B

YoY-13.2%

QoQ+307.9%

5Y CAGR+1.6%

10Y CAGR+33.0%

Bristol-Myers Squibb Co. generated $3.1B in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 13.2% from the same quarter a year earlier. Against the prior quarter it is up 307.9%.

Cash & Debt

$8.7B

YoY-30.8%

QoQ-8.9%

5Y CAGR-4.6%

10Y CAGR+11.5%

Bristol-Myers Squibb Co. held $8.7B in cash against $42.1B in long-term debt as of Q2 2026.

Dividends Per Share

$0.63

YoY+1.6%

QoQ0.0%

Bristol-Myers Squibb Co. paid $0.63 per share in dividends in Q2 2026. This represents an increase of 1.6% from the same quarter a year earlier. It is unchanged from the prior quarter.

Shares Outstanding

2.04B

YoY+0.4%

QoQ0.0%

5Y CAGR-1.7%

10Y CAGR+2.0%

Bristol-Myers Squibb Co. had 2.04B shares outstanding in Q2 2026. This represents an increase of 0.4% from the same quarter a year earlier. It is unchanged from the prior quarter.

Margins & Returns

Gross Margin

71.3%

YoY-1.2pp

QoQ+1.1pp

5Y change-7.8pp

10Y change-4.0pp

Bristol-Myers Squibb Co.'s gross margin was 71.3% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 1.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.1 percentage points.

Net Margin

25.6%

YoY+14.9pp

QoQ+2.3pp

5Y change+16.6pp

10Y change+1.6pp

Bristol-Myers Squibb Co.'s net profit margin was 25.6% in Q2 2026, showing the share of revenue converted to profit. This is up 14.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.3 percentage points.

Return on Equity

14.9%

YoY+7.4pp

QoQ+1.5pp

5Y change+12.0pp

10Y change+7.0pp

Bristol-Myers Squibb Co.'s ROE was 14.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 7.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.5 percentage points.

Operating Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$3.0B

YoY+14.7%

QoQ+11.7%

5Y CAGR+3.6%

Bristol-Myers Squibb Co. invested $3.0B in research and development in Q2 2026. This represents an increase of 14.7% from the same quarter a year earlier. Against the prior quarter it is up 11.7%.

Capital Expenditures

$305.0M

YoY-15.5%

QoQ-12.1%

5Y CAGR+7.7%

10Y CAGR+1.6%

Bristol-Myers Squibb Co. invested $305.0M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 15.5% from the same quarter a year earlier. Against the prior quarter it is down 12.1%.

Share Buybacks

Not reported for Q2 2026.

BMY Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BMY quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$49.2B	$48.2B-0.2%	$48.3B+7.3%	$45.0B-2.5%	$46.2B-0.5%	$46.4B+9.1%	$42.5B+62.6%	$26.1B+15.9%	$22.6B+8.6%	$20.8B+6.9%	$19.4B+17.3%	$16.6B+4.3%	$15.9B-3.1%	$16.4B-7.0%	$17.6B-17.1%	$21.2B
Cost of Revenue	$14.7B	$13.9B-0.2%	$14.0B+30.6%	$10.7B+5.5%	$10.1B+2.0%	$9.9B-15.6%	$11.8B+45.7%	$8.1B+24.9%	$6.5B+7.5%	$6.0B+21.0%	$5.0B+27.1%	$3.9B-0.6%	$3.9B-14.9%	$4.6B+0.2%	$4.6B-17.6%	$5.6B
Gross Profit	$34.5B	$34.3B-0.2%	$34.3B+0.1%	$34.3B-4.7%	$36.0B-1.2%	$36.4B+18.5%	$30.7B+70.2%	$18.1B+12.3%	$16.1B+9.6%	$14.7B+1.4%	$14.5B+14.5%	$12.7B+5.9%	$11.9B+1.5%	$11.8B-9.6%	$13.0B-16.8%	$15.6B
R&D Expenses	$10.7B	$10.0B-10.8%	$11.2B+20.0%	$9.3B-2.2%	$9.5B-6.7%	$10.2B+1.5%	$10.0B+63.4%	$6.1B-2.9%	$6.3B-2.1%	$6.5B+29.1%	$5.0B-15.3%	$5.9B+30.6%	$4.5B+21.5%	$3.7B-4.4%	$3.9B+1.7%	$3.8B
SG&A Expenses	$7.4B	$7.3B-13.6%	$8.4B+8.3%	$7.8B-0.5%	$7.8B+1.6%	$7.7B+0.4%	$7.7B+57.3%	$4.9B+7.0%	$4.6B-4.2%	$4.8B-4.6%	$5.0B+2.9%	$4.8B+0.4%	$4.8B-2.4%	$4.9B+17.0%	$4.2B+0.4%	$4.2B
Interest Expense	$1.7B	$1.9B-2.9%	$1.9B+67.0%	$1.2B-5.4%	$1.2B-7.6%	$1.3B-6.1%	$1.4B+116.5%	$656.0M+258.5%	$183.0M-6.6%	$196.0M+17.4%	$167.0M-9.2%	$184.0M-9.4%	$203.0M+2.0%	$199.0M+9.3%	$182.0M+25.5%	$145.0M
Income Tax	$2.6B	$2.3B+310.1%	$554.0M+38.5%	$400.0M-70.8%	$1.4B+26.2%	$1.1B-49.0%	$2.1B+40.2%	$1.5B+48.4%	$1.0B-75.4%	$4.2B+195.2%	$1.4B+215.7%	$446.0M+26.7%	$352.0M+13.2%	$311.0M+293.2%	-$161.0M-109.4%	$1.7B
Net Income	$9.3B	$7.1B+178.8%	-$8.9B-211.5%	$8.0B+26.8%	$6.3B-9.5%	$7.0B+177.6%	-$9.0B-362.1%	$3.4B-30.1%	$4.9B+388.6%	$1.0B-77.4%	$4.5B+184.8%	$1.6B-21.9%	$2.0B-21.8%	$2.6B+30.8%	$2.0B-47.2%	$3.7B
EPS (Basic)	N/A	$3.47+178.7%	-$4.41-213.7%	$3.88+30.6%	$2.97-5.7%	$3.15+178.9%	-$3.99-297.5%	$2.02-32.9%	$3.01+393.4%	$0.61-77.2%	$2.67+184.0%	$0.94-22.3%	$1.21-22.4%	$1.56+33.3%	$1.17-46.3%	$2.18
EPS (Diluted)	$4.54	$3.46+178.5%	-$4.41-214.2%	$3.86+30.8%	$2.95-5.4%	$3.12+178.2%	-$3.99-298.5%	$2.01-33.2%	$3.01+393.4%	$0.61-77.0%	$2.65+184.9%	$0.93-22.5%	$1.20-22.1%	$1.54+32.8%	$1.16-46.3%	$2.16
Diluted Shares (Avg)	N/A	2.04B+0.6%	2.03B-2.5%	2.08B-3.2%	2.15B-4.4%	2.25B-0.6%	2.26B+31.9%	1.71B+4.6%	1.64B-0.9%	1.65B-1.7%	1.68B+0.1%	1.68B+0.5%	1.67B+0.5%	1.66B-1.5%	1.69B-1.7%	1.72B

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$13.0B+5.7%	$11.5B+2.6%	$12.5B+1.3%	$12.2B+2.8%	$12.3B+0.6%	$11.2B-5.6%	$12.3B+7.5%	$11.9B+8.4%
Cost of Revenue	$3.7B+10.5%	$3.4B+12.8%	$4.1B-14.9%	$3.4B+16.2%	$3.4B+3.2%	$3.0B+3.4%	$4.8B+75.3%	$3.0B+18.0%
Gross Profit	$9.2B+3.9%	$8.1B-1.2%	$8.4B+11.6%	$8.8B-1.7%	$8.9B-0.4%	$8.2B-8.6%	$7.5B-13.8%	$8.9B+5.6%
R&D Expenses	$3.0B+14.7%	$2.6B+17.4%	$2.6B-19.0%	$2.5B+6.5%	$2.6B-11.0%	$2.3B-16.3%	$3.2B+28.8%	$2.4B+5.9%
SG&A Expenses	$1.8B+6.6%	$1.6B+2.1%	$2.2B+2.1%	$1.8B-9.8%	$1.7B-11.2%	$1.6B-33.1%	$2.1B+3.0%	$2.0B-1.0%
Interest Expense	$407.0M-16.1%	$411.0M-16.8%	$432.0M-12.9%	$480.0M-5.0%	$485.0M-6.9%	$494.0M+16.2%	$496.0M+57.0%	$505.0M+80.4%
Income Tax	$770.0M+67.4%	$561.0M+10.2%	$384.0M+287.9%	$919.0M+99.3%	$460.0M+215.6%	$509.0M+29.8%	$99.0M+212.5%	$461.0M+127.1%
Net Income	$3.3B+153.2%	$2.7B+9.0%	$1.1B+1409.7%	$2.2B+81.8%	$1.3B-22.0%	$2.5B+120.6%	$72.0M-95.9%	$1.2B-37.2%
EPS (Basic)	$1.62+153.1%	$1.31+8.3%	$0.54+1250.0%	$1.08+80.0%	$0.64-22.9%	$1.21+120.5%	$0.04-95.4%	$0.60-36.2%
EPS (Diluted)	$1.62+153.1%	$1.31+9.2%	$0.53+1225.0%	$1.08+80.0%	$0.64-22.9%	$1.20+120.4%	$0.04-95.4%	$0.60-35.5%
Diluted Shares (Avg)	2.05B+0.5%	2.05B+0.3%	N/A	2.04B+0.4%	2.04B+0.4%	2.04B+0.8%	N/A	2.03B-1.6%

Not reported in any period shown, so not listed: Operating Income, EBITDA.

BMY Balance Sheet

BMY quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$90.0B-2.8%	$92.6B-2.7%	$95.2B-1.7%	$96.8B-11.4%	$109.3B-7.7%	$118.5B-8.8%	$129.9B+271.4%	$35.0B+4.3%	$33.6B-0.5%	$33.7B+6.2%	$31.7B-5.9%	$33.7B-12.5%	$38.6B+7.5%	$35.9B+8.9%	$33.0B
Current Assets	$29.4B-1.3%	$29.8B-6.3%	$31.8B+16.5%	$27.3B-18.0%	$33.3B+10.2%	$30.2B+2.9%	$29.4B+65.7%	$17.7B+19.3%	$14.9B+8.4%	$13.7B+31.6%	$10.4B-28.7%	$14.6B-22.8%	$18.9B+98.7%	$9.5B-37.8%	$15.3B
Cash & Equivalents	$10.2B-1.3%	$10.3B-9.8%	$11.5B+25.7%	$9.1B-34.7%	$14.0B-3.9%	$14.5B+17.8%	$12.3B+78.6%	$6.9B+27.5%	$5.4B+27.9%	$4.2B+77.7%	$2.4B-57.2%	$5.6B+55.4%	$3.6B+116.5%	$1.7B-71.3%	$5.8B
Short-Term Investments	$464.0M-9.6%	$513.0M-37.1%	$816.0M+527.7%	$130.0M-95.6%	$3.0B+132.5%	$1.3B-57.8%	$3.0B+64.9%	$1.8B+32.9%	$1.4B-34.2%	$2.1B+12.1%	$1.9B+1.1%	$1.9B+98.5%	$939.0M-19.9%	$1.2B-60.3%	$3.0B
Inventory	$2.7B+5.2%	$2.6B-3.9%	$2.7B+13.8%	$2.3B+11.6%	$2.1B+1.0%	$2.1B-51.7%	$4.3B+259.2%	$1.2B+2.5%	$1.2B-6.0%	$1.2B+1.6%	$1.2B-21.7%	$1.6B+4.1%	$1.5B-9.6%	$1.7B+19.7%	$1.4B
Accounts Receivable	$9.6B+6.4%	$9.0B+1.5%	$8.9B+9.0%	$8.2B+2.2%	$8.0B+10.5%	$7.2B+11.5%	$6.5B+39.7%	$4.6B+6.6%	$4.3B+15.2%	$3.8B+28.0%	$2.9B+40.4%	$2.1B+24.3%	$1.7B-1.1%	$1.7B-24.1%	$2.3B
Long-Term Investments	$396.0M+23.8%	$320.0M-12.1%	$364.0M	$0	$0-100.0%	$433.0M-43.5%	$767.0M-56.8%	$1.8B-28.4%	$2.5B-8.8%	$2.7B-41.7%	$4.7B+5.7%	$4.4B+17.6%	$3.7B+6.4%	$3.5B+21.1%	$2.9B
Goodwill	$21.8B+0.2%	$21.7B+2.6%	$21.2B+0.1%	$21.1B+3.2%	$20.5B-0.2%	$20.5B-8.6%	$22.5B+244.0%	$6.5B-4.7%	$6.9B-0.2%	$6.9B-0.1%	$6.9B-2.1%	$7.0B-1.0%	$7.1B-7.1%	$7.6B+36.7%	$5.6B
Total Liabilities	$71.5B-6.1%	$76.2B+16.1%	$65.7B0.0%	$65.7B-10.4%	$73.3B-9.0%	$80.6B+3.0%	$78.2B+275.1%	$20.9B-3.9%	$21.7B+25.0%	$17.4B+0.2%	$17.3B-7.7%	$18.8B-19.7%	$23.4B+4.9%	$22.3B+30.1%	$17.1B
Current Liabilities	$23.4B-1.5%	$23.8B+6.8%	$22.3B+1.7%	$21.9B+0.1%	$21.9B+14.6%	$19.1B+4.2%	$18.3B+71.8%	$10.7B+11.4%	$9.6B+8.2%	$8.8B+10.3%	$8.0B-5.2%	$8.5B-32.0%	$12.4B+50.3%	$8.3B+6.4%	$7.8B
Non-Current Liabilities	$48.1B-8.2%	$52.4B+20.8%	$43.4B-0.9%	$43.8B-14.8%	$51.4B-16.4%	$61.5B+2.6%	$59.9B+487.4%	$10.2B-15.9%	$12.1B+42.5%	$8.5B-8.5%	$9.3B-9.7%	$10.3B-5.6%	$10.9B-21.9%	$14.0B+50.0%	$9.3B
Long-Term Debt	$42.9B-10.0%	$47.6B+29.9%	$36.7B+4.6%	$35.1B-11.5%	$39.6B-18.1%	$48.3B+11.4%	$43.4B+668.5%	$5.6B-19.1%	$7.0B+22.0%	$5.7B-12.7%	$6.5B-9.6%	$7.2B-9.3%	$8.0B+21.5%	$6.6B+22.2%	$5.4B
Total Equity	$18.5B+13.1%	$16.3B-44.5%	$29.4B-5.3%	$31.1B-13.6%	$35.9B-5.0%	$37.8B-26.7%	$51.6B+267.7%	$14.0B+19.5%	$11.7B-27.4%	$16.2B+13.4%	$14.3B-3.9%	$14.9B-2.0%	$15.2B+11.2%	$13.6B-14.6%	$16.0B
Retained Earnings	$16.9B+13.3%	$14.9B-48.2%	$28.8B+12.8%	$25.5B+7.1%	$23.8B+11.9%	$21.3B-38.3%	$34.5B+1.2%	$34.1B+9.3%	$31.2B-7.0%	$33.5B+6.0%	$31.6B-2.9%	$32.5B-1.2%	$33.0B+0.7%	$32.7B-1.0%	$33.1B

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$87.6B-7.4%	$86.5B-6.4%	$90.0B-2.8%	$96.9B+3.4%	$94.7B0.0%	$92.4B-6.7%	$92.6B-2.7%	$93.7B+2.6%
Current Assets	$28.6B-14.0%	$27.2B-11.6%	$29.4B-1.3%	$35.6B+26.9%	$33.2B+23.5%	$30.8B+7.4%	$29.8B-6.3%	$28.1B+1.6%
Cash & Equivalents	$8.7B-30.8%	$9.6B-12.0%	$10.2B-1.3%	$15.7B+99.3%	$12.6B+100.2%	$10.9B+16.6%	$10.3B-9.8%	$7.9B+5.0%
Short-Term Investments	$2.3B+133.6%	$912.0M+0.6%	$464.0M-9.6%	$776.0M+280.4%	$1.0B+178.9%	$907.0M+166.8%	$513.0M-37.1%	$204.0M+19.3%
Inventory	$2.7B0.0%	$2.8B+3.4%	$2.7B+5.2%	$2.8B-17.2%	$2.7B-11.0%	$2.7B-10.7%	$2.6B-3.9%	$3.3B+36.8%
Accounts Receivable	$9.1B-6.5%	$7.9B-12.3%	$9.6B+6.4%	$9.6B+3.3%	$9.7B-0.4%	$9.1B+2.7%	$9.0B+1.5%	$9.3B+10.8%
Long-Term Investments	$397.0M+14.7%	$366.0M+6.4%	$396.0M+23.8%	$406.0M+25.3%	$346.0M-3.1%	$344.0M-6.3%	$320.0M-12.1%	$324.0M
Goodwill	$21.7B-0.2%	$21.7B0.0%	$21.8B+0.2%	$21.7B0.0%	$21.8B+0.2%	$21.7B0.0%	$21.7B+2.6%	$21.8B+2.9%
Total Liabilities	$65.3B-15.4%	$66.4B-11.5%	$71.5B-6.1%	$78.3B+2.4%	$77.2B-0.5%	$75.0B-9.1%	$76.2B+16.1%	$76.5B+22.9%
Current Liabilities	$18.7B-32.2%	$19.2B-20.4%	$23.4B-1.5%	$28.1B+24.3%	$27.5B+18.3%	$24.1B-6.8%	$23.8B+6.8%	$22.6B-3.5%
Non-Current Liabilities	$46.7B-6.0%	$47.2B-7.3%	$48.1B-8.2%	$50.2B-6.8%	$49.7B-8.6%	$50.9B-10.2%	$52.4B+20.8%	$53.8B+39.0%
Long-Term Debt	$42.1B-5.3%	$42.2B-8.7%	$42.9B-10.0%	$44.5B-8.6%	$44.5B-9.0%	$46.2B-6.7%	$47.6B+29.9%	$48.7B+51.5%
Total Equity	$22.3B+28.0%	$20.1B+15.4%	$18.5B+13.1%	$18.6B+8.2%	$17.4B+2.5%	$17.4B+5.5%	$16.3B-44.5%	$17.1B-40.9%
Retained Earnings	$20.3B+25.8%	$18.3B+13.5%	$16.9B+13.3%	$17.1B+6.2%	$16.2B+0.3%	$16.1B+3.0%	$14.9B-48.2%	$16.1B-43.0%

BMY Cash Flow Statement

BMY quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$12.8B	$14.2B-6.8%	$15.2B+9.6%	$13.9B+6.1%	$13.1B-19.4%	$16.2B+15.3%	$14.1B+71.2%	$8.2B+16.2%	$7.1B+34.0%	$5.3B+72.5%	$3.1B+45.3%	$2.1B-33.1%	$3.1B-11.2%	$3.5B-48.9%	$6.9B+43.4%	$4.8B
Depreciation & Amortization	N/A	$4.0B-58.2%	$9.6B-1.6%	$9.8B-5.0%	$10.3B-3.8%	$10.7B+2.9%	$10.4B+494.5%	$1.7B+174.1%	$637.0M-19.3%	$789.0M+106.5%	$382.0M+1.6%	$376.0M-19.5%	$467.0M-38.8%	$763.0M+12.0%	$681.0M+8.4%	$628.0M
Stock-Based Compensation	N/A	$553.0M+9.1%	$507.0M-2.1%	$518.0M+13.3%	$457.0M-21.6%	$583.0M-25.2%	$779.0M+76.6%	$441.0M+99.5%	$221.0M+11.1%	$199.0M-2.9%	$205.0M-12.8%	$235.0M+10.3%	$213.0M+11.5%	$191.0M+24.0%	$154.0M-4.3%	$161.0M
Capital Expenditures	$1.3B	$1.3B+5.0%	$1.2B+3.2%	$1.2B+8.1%	$1.1B+14.9%	$973.0M+29.2%	$753.0M-9.9%	$836.0M-12.1%	$951.0M-9.9%	$1.1B-13.2%	$1.2B+48.2%	$820.0M+55.9%	$526.0M-2.0%	$537.0M-2.0%	$548.0M+49.3%	$367.0M
Free Cash Flow	$11.4B	$12.8B-7.9%	$13.9B+10.2%	$12.7B+5.9%	$11.9B-21.6%	$15.2B+14.5%	$13.3B+80.3%	$7.4B+20.6%	$6.1B+44.9%	$4.2B+129.0%	$1.8B+43.4%	$1.3B-51.0%	$2.6B-12.8%	$3.0B-52.9%	$6.4B+42.9%	$4.5B
Investing Cash Flow	-$4.9B	-$4.1B+80.6%	-$21.4B-830.4%	-$2.3B-116.1%	-$1.1B-97.4%	-$538.0M+95.0%	-$10.9B-9.5%	-$9.9B-395.7%	-$2.0B-2930.3%	-$66.0M-104.5%	$1.5B+194.1%	-$1.6B-229.3%	$1.2B+312.6%	-$572.0M+91.5%	-$6.7B-368.1%	-$1.4B
Financing Cash Flow	-$11.7B	-$10.3B-301.8%	$5.1B+154.4%	-$9.4B+44.5%	-$17.0B-4.5%	-$16.2B-1309.6%	-$1.2B-115.1%	$7.6B+315.6%	-$3.5B+13.3%	-$4.1B-53.7%	-$2.7B+26.8%	-$3.6B-48.7%	-$2.4B-128.2%	-$1.1B+75.4%	-$4.3B-63.1%	-$2.7B
Dividends Paid	$5.1B	$5.0B+3.7%	$4.9B+2.5%	$4.7B+2.4%	$4.6B+5.4%	$4.4B+7.9%	$4.1B+52.1%	$2.7B+2.5%	$2.6B+1.4%	$2.6B+1.2%	$2.5B+2.8%	$2.5B+3.3%	$2.4B+3.9%	$2.3B+1.0%	$2.3B+1.4%	$2.3B
Share Buybacks	N/A	$0	$0-100.0%	$5.2B-35.6%	$8.0B+27.3%	$6.3B+306.7%	$1.5B-78.8%	$7.3B+2181.3%	$320.0M-87.0%	$2.5B+968.8%	$231.0M	N/A	N/A	$433.0M-82.0%	$2.4B+96.8%	$1.2B

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$3.4B-13.4%	$1.1B-43.5%	$2.0B-55.5%	$6.3B+12.9%	$3.9B+68.4%	$2.0B-31.1%	$4.4B+4.4%	$5.6B+17.7%
Depreciation & Amortization	$610.0M-40.7%	$594.0M-41.3%	$977.0M-48.0%	$1.0B-60.0%	$1.0B-59.8%	$1.0B-60.0%	$1.9B-23.7%	$2.6B+4.7%
Stock-Based Compensation	$135.0M-2.2%	$146.0M+1.4%	N/A	$139.0M+7.8%	$138.0M+10.4%	$144.0M+8.3%	N/A	$129.0M-2.3%
Capital Expenditures	$305.0M-15.5%	$347.0M+33.5%	$370.0M-2.1%	$320.0M-1.2%	$361.0M+37.8%	$260.0M-8.5%	$378.0M+14.5%	$324.0M-5.3%
Free Cash Flow	$3.1B-13.2%	$757.0M-55.3%	$1.6B-60.5%	$6.0B+13.7%	$3.6B+72.3%	$1.7B-33.6%	$4.1B+3.5%	$5.3B+19.5%
Investing Cash Flow	-$1.6B-241.2%	-$131.0M+73.7%	-$1.5B-643.9%	-$1.7B-677.2%	-$473.0M+64.1%	-$499.0M+97.5%	-$196.0M+85.4%	-$219.0M+46.6%
Financing Cash Flow	-$2.6B-43.2%	-$1.6B-57.1%	-$6.0B-267.2%	-$1.5B+61.3%	-$1.8B+54.4%	-$993.0M-106.8%	-$1.6B-269.8%	-$3.9B+25.3%
Dividends Paid	$1.3B+2.0%	$1.3B+2.0%	$1.3B+3.6%	$1.3B+3.9%	$1.3B+3.7%	$1.3B+3.8%	$1.2B+5.0%	$1.2B+2.1%
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%

BMY Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BMY quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	71.1%0.0pp	71.1%-5.2pp	76.2%-1.8pp	78.0%-0.5pp	78.6%+6.3pp	72.3%+3.2pp	69.1%-2.2pp	71.3%+0.7pp	70.7%-3.9pp	74.5%-1.9pp	76.4%+1.2pp	75.2%+3.4pp	71.8%-2.0pp	73.8%+0.2pp	73.7%
Net Margin	14.6%+33.2pp	-18.5%-36.4pp	17.8%+4.1pp	13.7%-1.4pp	15.1%+36.3pp	-21.2%-34.4pp	13.2%-8.7pp	21.8%+17.0pp	4.9%-18.1pp	22.9%+13.5pp	9.4%-3.2pp	12.6%-3.0pp	15.6%+4.5pp	11.1%-6.3pp	17.5%
Return on Equity	38.2%+93.0pp	-54.8%-82.0pp	27.3%+6.9pp	20.4%+0.9pp	19.5%+43.3pp	-23.8%-30.5pp	6.7%-28.4pp	35.1%+26.5pp	8.6%-19.0pp	27.6%+16.6pp	11.0%-2.5pp	13.5%-3.4pp	16.9%+2.5pp	14.4%-8.9pp	23.3%
Return on Assets	7.8%+17.5pp	-9.7%-18.1pp	8.4%+1.9pp	6.5%+0.1pp	6.4%+14.0pp	-7.6%-10.3pp	2.6%-11.4pp	14.1%+11.1pp	3.0%-10.2pp	13.2%+8.3pp	4.9%-1.0pp	5.9%-0.7pp	6.6%+1.2pp	5.5%-5.8pp	11.3%
Current Ratio	1.260.0x	1.25-0.2x	1.43+0.2x	1.25-0.3x	1.52-0.1x	1.580.0x	1.60-0.1x	1.66+0.1x	1.550.0x	1.55+0.3x	1.30-0.4x	1.73+0.2x	1.52+0.4x	1.15-0.8x	1.97
Debt-to-Equity	2.32-0.6x	2.91+1.7x	1.25+0.1x	1.130.0x	1.10-0.2x	1.28+0.4x	0.84+0.4x	0.40-0.2x	0.59+0.2x	0.35-0.1x	0.460.0x	0.490.0x	0.530.0x	0.48+0.1x	0.34
Asset Turnover	0.540.0x	0.520.0x	0.470.0x	0.48+0.1x	0.42+0.1x	0.36+0.2x	0.20-0.4x	0.640.0x	0.620.0x	0.58+0.1x	0.52+0.1x	0.470.0x	0.42-0.1x	0.49-0.2x	0.64
FCF Margin	26.7%-2.2pp	28.9%+0.8pp	28.1%+2.2pp	25.9%-7.0pp	32.8%+1.6pp	31.3%+3.1pp	28.2%+1.1pp	27.1%+6.8pp	20.3%+10.8pp	9.5%+1.7pp	7.8%-8.8pp	16.5%-1.9pp	18.4%-17.9pp	36.3%+15.2pp	21.1%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	71.3%-1.2pp	70.2%-2.7pp	67.2%+6.2pp	71.9%-3.2pp	72.5%-0.7pp	72.9%-2.4pp	61.0%-15.1pp	75.1%-2.0pp
Net Margin	25.6%+14.9pp	23.3%+1.4pp	8.7%+8.1pp	18.0%+7.8pp	10.7%-3.1pp	21.9%	0.6%-14.8pp	10.2%-7.4pp
Return on Equity	14.9%+7.4pp	13.3%-0.8pp	5.9%+5.4pp	11.9%+4.8pp	7.5%-2.4pp	14.1%+86.4pp	0.4%-5.5pp	7.1%+0.4pp
Return on Assets	3.8%+2.4pp	3.1%+0.4pp	1.2%+1.1pp	2.3%+1.0pp	1.4%-0.4pp	2.7%+14.7pp	0.1%-1.8pp	1.3%-0.8pp
Current Ratio	1.53+0.3x	1.42+0.1x	1.260.0x	1.270.0x	1.21+0.1x	1.28+0.2x	1.25-0.2x	1.24+0.1x
Debt-to-Equity	1.89-0.7x	2.10-0.6x	2.32-0.6x	2.40-0.4x	2.55-0.3x	2.65-0.3x	2.91+1.7x	2.84+1.7x
Asset Turnover	0.150.0x	0.130.0x	0.140.0x	0.130.0x	0.130.0x	0.120.0x	0.130.0x	0.130.0x
FCF Margin	23.8%-5.2pp	6.6%-8.5pp	12.8%-20.1pp	49.0%+4.7pp	29.0%+12.1pp	15.1%-6.4pp	32.9%-1.3pp	44.3%+4.1pp

Not reported in any period shown, so not listed: Operating Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Bristol-Myers Squibb Co. BMY	FY2025	$48.2B	$7.1B	14.6%	$121.7B	33/100
Pfizer Inc. PFE	FY2025	$62.6B	$7.8B	12.4%	$156.2B	33/100
Amgen Inc AMGN	FY2025	$36.8B	$7.7B	21.0%	$217.9B	63/100
Gilead Sciences Inc GILD	FY2025	$29.4B	$8.5B	28.9%	$179.3B	64/100

Where Bristol-Myers Squibb Co. Ranks

Frequently Asked Questions

What is Bristol-Myers Squibb Co.'s annual revenue?

Bristol-Myers Squibb Co. (BMY) reported $48.2B in total revenue for fiscal year 2025. This represents a -0.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Bristol-Myers Squibb Co.'s revenue growing?

Bristol-Myers Squibb Co. (BMY) revenue declined by 0.2% year-over-year, from $48.3B to $48.2B in fiscal year 2025.

Is Bristol-Myers Squibb Co. profitable?

Yes, Bristol-Myers Squibb Co. (BMY) reported a net income of $7.1B in fiscal year 2025, with a net profit margin of 14.6%.

How much debt does Bristol-Myers Squibb Co. have?

As of fiscal year 2025, Bristol-Myers Squibb Co. (BMY) had $10.2B in cash and equivalents against $42.9B in long-term debt.

What is Bristol-Myers Squibb Co.'s gross margin?

Bristol-Myers Squibb Co. (BMY) had a gross margin of 71.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Bristol-Myers Squibb Co.'s net profit margin?

Bristol-Myers Squibb Co. (BMY) had a net profit margin of 14.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Bristol-Myers Squibb Co. pay dividends?

Yes, Bristol-Myers Squibb Co. (BMY) paid $2.49 per share in dividends during fiscal year 2025.

What is Bristol-Myers Squibb Co.'s return on equity (ROE)?

Bristol-Myers Squibb Co. (BMY) has a return on equity of 38.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Bristol-Myers Squibb Co.'s free cash flow?

Bristol-Myers Squibb Co. (BMY) generated $12.8B in free cash flow during fiscal year 2025. This represents a -7.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Bristol-Myers Squibb Co.'s operating cash flow?

Bristol-Myers Squibb Co. (BMY) generated $14.2B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Bristol-Myers Squibb Co.'s total assets?

Bristol-Myers Squibb Co. (BMY) had $90.0B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Bristol-Myers Squibb Co.'s capital expenditures?

Bristol-Myers Squibb Co. (BMY) invested $1.3B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Bristol-Myers Squibb Co. spend on research and development?

Bristol-Myers Squibb Co. (BMY) invested $10.0B in research and development during fiscal year 2025.

How many shares does Bristol-Myers Squibb Co. have outstanding?

Bristol-Myers Squibb Co. (BMY) had 2.04B shares outstanding as of fiscal year 2025.

What is Bristol-Myers Squibb Co.'s current ratio?

Bristol-Myers Squibb Co. (BMY) had a current ratio of 1.26 as of fiscal year 2025, which is considered adequate.

What is Bristol-Myers Squibb Co.'s debt-to-equity ratio?

Bristol-Myers Squibb Co. (BMY) had a debt-to-equity ratio of 2.32 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Bristol-Myers Squibb Co.'s return on assets (ROA)?

Bristol-Myers Squibb Co. (BMY) had a return on assets of 7.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Bristol-Myers Squibb Co.'s P/E ratio?

Bristol-Myers Squibb Co. (BMY) trades at 13.1x earnings, its market capitalization divided by net income of $9.3B net income, trailing 12 months to June 30, 2026. The market capitalization is $121.7B as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Bristol-Myers Squibb Co.'s price-to-sales ratio?

Bristol-Myers Squibb Co. (BMY) trades at 2.5x sales, its market capitalization divided by revenue of $49.2B revenue, trailing 12 months to June 30, 2026. The market capitalization is $121.7B as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Bristol-Myers Squibb Co.'s Piotroski F-Score?

Bristol-Myers Squibb Co. (BMY) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Bristol-Myers Squibb Co.'s earnings high quality?

Bristol-Myers Squibb Co. (BMY) has an earnings quality ratio of 2.01x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Bristol-Myers Squibb Co.?

Bristol-Myers Squibb Co. (BMY) scores 33 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.